Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

References

• IASP Task Force in Taxonomy. Pain terms: a current list with definitions and notes on usage. In: Merksey H, Bogduk N, editors. Classifications of chronic pain syndromes and definitions of pain terms. 2nd edn. Seattle: IASP, 1994. pp.206–13
   Google Scholar
• Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991;47:644–66
   PubMed Web of Science ®Google Scholar
• Dworkin RH. An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002;18:343–9
   PubMed Web of Science ®Google Scholar
• Karlsten R, Gordh T. How do drugs relieve neurogenic pain? Drugs Aging 1997;11:398–412
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Lyrica: European Public Assessment report. Scientific discussion. Sept 2006. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/lyrica/lyrica.htm [Last accessed 11 Dec 2006]
   Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350–54
   PubMed Web of Science ®Google Scholar
• Dubinsky RM, Kabbany H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63:959–65
   Google Scholar
• Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment and prevention. N Engl J Med 1996;335:32–42
   PubMed Web of Science ®Google Scholar
• Gálvez R, Marsal C, Vidal J, et al. El dolor neuropático como causa de ansiedad, depresión y trastornos del sueño en condiciones de práctica médica habitual: resultados del estudio naturalístico DONEGA [in Spanish]. Rev Soc Esp Dolor 2006;2:81–95
   Google Scholar
• Galvez R, Marsal C, Vidal J, et al. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain 2007;11:244–55 [Epub ahead of print 24 Mar 2006]
   Google Scholar
• Mc Dermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127–35
   PubMed Web of Science ®Google Scholar
• McCarberg B, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Manag Care 2006;12:263–8
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Backonja M, Rowbotham MC, et al. Diagnosis, mechanisms and treatment recommendations. Arch Neurol 2003;60:1524–33
   PubMed Web of Science ®Google Scholar
• Rodríguez-López MJ. Papel de los FAE en el tratamiento del dolor neuropático. Mecanismos de acción de la gabapentina [in Spanish]. Rev Soc Esp Dolor 2002;9:13–8
   Google Scholar
• Gee NS, Brown JP, Dissanayake JU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768–76
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229–36
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295: 1086–93
   Google Scholar
• Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93: 91–6
   Google Scholar
• Servicio Vasco de Salud. Comité de Evaluación de Nuevos Medicamentos. Nuevo medicamento a examen: Pregabalina. No.120, 2006. Available from http://www.osanet.euskadi.net (profesionales) [Last accessed 19 Dec 2006]
   Google Scholar
• Institut Catalá de la Salut. Informe Estándard: Pregabalina. 2006. Available from http://www.gencat.net/ics/professionals/farmacia.htm. [Last accessed 19 Dec 2006]
   Google Scholar
• Wesche D, Bockbrader H. The pharmacokinetic properties of pregabalin and gabapentin: differences and similarities. Eur J Neurology 2005;12:259 [abstract P2368]
   Google Scholar
• Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother 2006;6:1629–35
   PubMedGoogle Scholar
• Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs today (Barc) 1995;31:613–9
   Google Scholar
• Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin. J Pain 2005;6:S29 [abstract]
   Google Scholar
• Zelman DC, Smith MY, Hoffman D, et al. Acceptable, manageable, and tolerable days: patient daily goals for medication management of persistent pain. J Pain Symptom Manage 2004;28:474–87
   PubMed Web of Science ®Google Scholar
• Rubio S. Estudios de farmacoeconomía a través de modelos basados en el análsis de decisión. In: Domínguez-Gil A y Soto J, editors. Farmacoeconomía e investigación de resultados en salud: principios y práctica. 3rd edn. Real Academia Nacional de Farmacia, 2002. pp.263–5
   Google Scholar
• Goldie S. Public health policy and cost-effectiveness analyses. J Natl Cancer Inst Monogr 2003;31:102–10
   PubMedGoogle Scholar
• Kuntz K, Weinstein M. Modeling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: Merging theory with practice. New York: Oxford University Press, 2001. pp.141–71
   Google Scholar
• Halpern E, Weinstein M, Hunink M, et al. Representing first-and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314–22
   PubMed Web of Science ®Google Scholar
• Vera-Lonch M, Dukes E, Delea TE, et al. Treatment of peripheral neuropathic pain: a simulation model. Eur J Pain 2006;10:279–85
   Google Scholar
• Zelman D, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005;115:29–36
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain 2005;115:254–63
   PubMed Web of Science ®Google Scholar
• Zelman D, Gore M, Dukes E, et al. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 2005;29:401–10
   PubMed Web of Science ®Google Scholar
• Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277–84
   PubMed Web of Science ®Google Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled study. JAMA 1998;280:1831–36
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, et al. Gabapentin in the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837–42
   PubMed Web of Science ®Google Scholar
• Rejas J, Pérez P, Gálvez R, et al. Utility mapping in patients with chronic nociceptive or neuropathic pain using the health utility index mark 3: a Spanish perspective. 2006 International Society for Quality of Life Research meeting abstracts [www.isoqol. org/2006mtgabstracts]. The QLR Journal A-129 [abstract 1616]
   Google Scholar
• Soikos, Centro de Estudios en Economía de la Salud y Política Social. Base de datos de costes sanitarios. Versión 2.2. Barcelona 2005.
   Google Scholar
• Catálogo de Especialidades Farmacéuticas de 2006. Consejo General de Colegios Oficiales de Farmacéuticos de España. Madrid 2006
   Google Scholar
• Berger A, Dukes EM, Oster G. Clinical characteristic and economics costs of patients with painful neuropathic disorders. J Pain 2004;5:143–9
   Google Scholar
• Rodríguez M, García A; on behalf of the Collaborative Group for study of Neuropathic Pain of the Spanish Society of Pain. Costs and health resources comparison of Neuropathic Pain (NeP) management patterns in Spain: the pain unit model vs. a composite of primary Care and other specialized care model. 11th World Congress of Pain, 21–26 Aug, 2005. Sydney, Australia. [abstract]
   Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;4:334–43
   Google Scholar
• Tengs OT, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369–90
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992;146:473–81
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004
   Google Scholar
• Commission on Macroeconomics and Health. (2001) Report of the Commission on Macroeconomics and Health – Macroeconomics and health: Investing in health for economic development Geneva: World Health Organization. Available from http://www3.who.int/whosis/cmh/cmh_report/report.cfm?path=whosis,cmh,cmh_report&language=english [Last accessed 19 Dec 2006]
   Google Scholar
• World Health Organization. (2002) World health report 2002 – reducing risks, promoting health life. Geneva: World Health Organization. Available from http://www.who.int/whr/2002/en [Last accessed 19 Dec 2006]
   Google Scholar
• International Monetary Fund. Economic outlook database, September 2006. Available from http://www.imf.org/external/pubs/ft/weo/2006/02/data/index.aspx. Last accessed 19 Dec 2006]
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices – modeling studies. Value Health 2003;6:9–17
   PubMed Web of Science ®Google Scholar
• Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28:1922–34
   Google Scholar